Search

Displaying results 1961 - 1970 of 10000 in total
  1. Drug

    PX-102

    go.drugbank.com/drugs/DB15416
    Investigational

    PX-102 is under investigation in clinical trial NCT01998672 (Multiple Ascending Oral Dose Phase I Study With Px-102).

  2. Drug

    Nevanimibe

    go.drugbank.com/drugs/DB16254
    Investigational

    Nevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome).

    Synonyms: Atr-101 free base
  3. Drug

    AMY-101

    go.drugbank.com/drugs/DB14803
    Investigational

    AMY-101 is under investigation in clinical trial NCT03694444 (A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis). … AMY-101, also known as compstatin 40, is a peptidic inhibitor of the central complement component C3.

    Synonyms: AMY 101, S3,S13-Cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)
  4. Drug

    RAP-103

    go.drugbank.com/drugs/DB28444
    Experimental

    RAP-103 is a multi-chemokine receptor antagonist which is orally active.[A274606, A274611]

  5. Drug

    ST-101

    go.drugbank.com/drugs/DB12621
    Investigational

    ST-101 is a small peptide antagonist of C/EBPβ and T-type calcium channel activator. ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease.[A260411]

    Synonyms: ST-101 (D-AMINO ACID PEPTIDE)
  6. Drug

    Polyethylene glycol 400

    go.drugbank.com/drugs/DB11077
    ApprovedInvestigational

    PEG "400" indicates that the average molecular weight of the specific PEG is 400 [L1788]. … [L1787] Polyethylene glycol 400 (PEG 400) is a low-molecular-weight grade of polyethylene glycol with a low-level toxicity.

    Mixtures: POLIETILENGLICOL 400 0.4% - PROPILENGLICOL 0.3% SOLUCIÓN OFTALMICA, VISINA XT (ADVANCED RELIEF)Synonyms: PEG-400, macrogol 400
  7. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical. … It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder.

    Products: URITOS (TABLETS 0.1 MG), URITOS TABLETS 0.1 MG
  8. Drug

    AMP-101

    go.drugbank.com/drugs/DB18253
    Experimental

    AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.

  9. Drug

    CB-103

    go.drugbank.com/drugs/DB15279
    Investigational

    CB-103 is under investigation in clinical trial NCT03422679 (Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies).

    Salts: CB-103 hydrochloride
  10. Drug

    TSHA-102

    go.drugbank.com/drugs/DB18599
    Investigational

    TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene.